Cerebrospinal fluid N-224 tau helps discriminate Alzheimer’s disease from subjective cognitive decline and other dementias
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1758-9193
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Cerebrospinal fluid N-224 tau helps discriminate Alzheimer’s disease from subjective cognitive decline and other dementias ; volume:13 ; number:1 ; day:8 ; month:2 ; year:2021 ; pages:1-12 ; date:12.2021
Alzheimer's research & therapy ; 13, Heft 1 (8.2.2021), 1-12, 12.2021
- Urheber
-
Cicognola, Claudia
Hansson, Oskar
Scheltens, Philip
Kvartsberg, Hlin
Zetterberg, Henrik
Teunissen, Charlotte E.
Blennow, Kaj
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s13195-020-00756-6
- URN
-
urn:nbn:de:101:1-2021030400085620545143
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:32 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Cicognola, Claudia
- Hansson, Oskar
- Scheltens, Philip
- Kvartsberg, Hlin
- Zetterberg, Henrik
- Teunissen, Charlotte E.
- Blennow, Kaj
- SpringerLink (Online service)
Ähnliche Objekte (12)
Heterogeneity of Alzheimer’s disease: consequence for drug trials?
A decade of Alzheimer’s Research & Therapy: reflections on the past, present, and future
The “rights” of precision drug development for Alzheimer’s disease
Antibodies against phosphorylcholine are not altered in plasma of patients with Alzheimer’s disease
Fluid biomarkers in Alzheimer’s disease – current concepts
Cerebro-spinal fluid biomarker levels: phosphorylated tau (T) and total tau (N) as markers for rate of progression in Alzheimer’s disease
Clinical Features of Patients with Alzheimer’s Disease and a History of Traumatic Brain Injury
The plasma peptides of Alzheimer’s disease
Eyes-closed task-free electroencephalography in clinical trials for Alzheimer’s disease: an emerging method based upon brain dynamics
Changes in cerebrospinal fluid and blood plasma levels of IGF-II and its binding proteins in Alzheimer’s disease: an observational study
Blood‐based biomarkers for Alzheimer's disease
Reproducibility of EEG functional connectivity in Alzheimer’s disease
Heterogeneity of Alzheimer’s disease: consequence for drug trials?
A decade of Alzheimer’s Research & Therapy: reflections on the past, present, and future
The “rights” of precision drug development for Alzheimer’s disease
Antibodies against phosphorylcholine are not altered in plasma of patients with Alzheimer’s disease
Fluid biomarkers in Alzheimer’s disease – current concepts
Cerebro-spinal fluid biomarker levels: phosphorylated tau (T) and total tau (N) as markers for rate of progression in Alzheimer’s disease
Clinical Features of Patients with Alzheimer’s Disease and a History of Traumatic Brain Injury
The plasma peptides of Alzheimer’s disease
Eyes-closed task-free electroencephalography in clinical trials for Alzheimer’s disease: an emerging method based upon brain dynamics
Changes in cerebrospinal fluid and blood plasma levels of IGF-II and its binding proteins in Alzheimer’s disease: an observational study
Blood‐based biomarkers for Alzheimer's disease
Reproducibility of EEG functional connectivity in Alzheimer’s disease
Heterogeneity of Alzheimer’s disease: consequence for drug trials?
A decade of Alzheimer’s Research & Therapy: reflections on the past, present, and future
The “rights” of precision drug development for Alzheimer’s disease
Antibodies against phosphorylcholine are not altered in plasma of patients with Alzheimer’s disease
Fluid biomarkers in Alzheimer’s disease – current concepts
Cerebro-spinal fluid biomarker levels: phosphorylated tau (T) and total tau (N) as markers for rate of progression in Alzheimer’s disease
Clinical Features of Patients with Alzheimer’s Disease and a History of Traumatic Brain Injury
The plasma peptides of Alzheimer’s disease
Eyes-closed task-free electroencephalography in clinical trials for Alzheimer’s disease: an emerging method based upon brain dynamics
Changes in cerebrospinal fluid and blood plasma levels of IGF-II and its binding proteins in Alzheimer’s disease: an observational study
Blood‐based biomarkers for Alzheimer's disease